Biogen Inc. (BIIB) News & EventsBIIBNews & EventsBiogen Inc.

Stock Futures Muted Ahead of Fed Rate Decision

Stock futures are muted Wednesday as investors await the Federal Reserve's interest rate decision and a round of technology earnings that could potentially shape market direction through the remainder of the summer.The Federal Reserve concludes its two-day policy meeting this afternoon, with markets expecting policymakers to leave the benchmark federal funds rate unchanged. The primary focus will be Fed Chair Kevin Warsh's post-meeting press conference for clues on how the central bank views inflation, economic growth and the path of interest rates.Corporate earnings remain the market's other major catalyst. Microsoft and Meta Platforms are scheduled to report after the closing bell, with investors looking for evidence that continued multibillion-dollar investments in artificial intelligence are translating into stronger cloud growth, advertising revenue and profitability.Semiconductor stocks remain under pressure following disappointing market reactions to earnings from South Korean memory chipmaker SK Hynix despite strong headline results. Investors continue to question whether AI infrastructure spending can support current valuations as competition from Chinese chipmakers increases.Investors will monitor developments in the Middle East after renewed regional tensions pushed oil prices higher, reviving concerns that energy-driven inflation could complicate the Federal Reserve's policy outlook. With monetary policy, Big Tech earnings and geopolitical developments all converging, markets are preparing for elevated volatility through the end of the week.In pre-market trading, S&P 500 futures slid 0.01%, Nasdaq futures fell 0.06% and Dow futures declined 0.64%.Check out this morning's top movers from around Wall Street, compiled by The Fly.UP AFTER EARNINGS -Manhattan Associatesup 13%Rocky Brandsup 12%Generacup 9%Amphenolup 6%Tevaup 6%Seagateup 5%Fordup 5%Deutsche Bankup 2%Biogenup 1%General Dynamicsup 1%DOWN AFTER EARNINGS -Lemonadedown 14%Vertivdown 10%VF Corp.down 9%Skyworksdown 8%Humanadown 4%Procter & Gambledown 3%NXP Semiconductorsdown 2%WMdown 2%SK Hynixdown 1%Visadown 1%OneMaindown 1%

Biogen Reports Q2 Revenue of $2.736B, Exceeding Expectations

Reports Q2 revenue $2.736B, consensus $2.46B. "This quarter is a reflection of the significant progress Biogen has made repositioning the company for long term growth. Not only did our growth portfolio revenue exceed that of our legacy MS portfolio, delivering 24% of year-over year growth, we also delivered strong revenue performance from our two recently acquired products, providing an opportunity for our pipeline to build on a growing business," said President and Chief Executive Officer Christopher Viehbacher. "At the same time, our scientific leadership continues to translate into commercial momentum, with a successful launch of SPINRAZA HD and historic approval of LEQEMBI IQLIK at-home initiation. As we enter a period of registrational data readouts beginning this year, we are realizing our vision for the New Biogen one positioned for sustainable growth with a growing commercial business, a multi year late stage data flow, and an expanding early stage pipeline."